QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
The group now has 320 approvals and has so far filed over 400 ANDAs
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
The government has taken all the effective measures to make healthcare affordable
Subscribe To Our Newsletter & Stay Updated
